DDInter1579 DDInter1376
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Remifentanil {u} (Compound) resembles {v} (Compound) Alfentanil
Remifentanil {u} (Compound) resembles {v} (Compound) Fentanyl
Remifentanil {u} (Compound) binds {v} (Gene) OPRM1
Remifentanil {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Remifentanil {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Remifentanil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Remifentanil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclizine
Remifentanil {u} may lead to a major life threatening interaction when taken with {v} Granisetron
Remifentanil {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Remifentanil (Compound) resembles Alfentanil (Compound)
Remifentanil (Compound) resembles Fentanyl (Compound)
Remifentanil (Compound) binds OPRM1 (Gene)
Remifentanil (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Remifentanil (Compound) causes Cardiac disorder (Side Effect)
Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Remifentanil may lead to a major life threatening interaction when taken with Granisetron
Remifentanil may lead to a major life threatening interaction when taken with Iohexol